New era of dialysis: expanded haemodialysis (HDx)

Authors

DOI:

https://doi.org/10.22141/2307-1257.8.1.2019.157797

Keywords:

haemodialysis, expanded haemodialysis, ­THERANOVA, individualization of haemodialysis, HDx, removal of large medium uremic toxins, haemodiafiltration

Abstract

The article is addressed to practical physicians involved in renal replacement therapy, mainly haemodialysis (HD). The article presents a new method for haemodialysis — expanded haemodialysis, assesses its efficiency, and is focused on the problem of large medium molecules elimination. The essence of the method is to use the THERANOVA haemodialyser with the usual infrastructure. The term expanded HD (HDx) has been proposed to determine a method where diffusion and convection are conveniently combined in ­THERANOVA dialysis with a hollow fibre and equipped with a membrane for middle cut-off. A standard dialysis device can easily perform this technique without special software or additional sophisticated technology. To achieve optimal clearance in the system blood flow 300 ml/min and dialysate flow ≥ 500 ml/min is sufficient. In HDx, the convection flow is supported by internal filtering, but it is offset by the reverse filtering mechanism inside the filter. The special configuration of the membrane with reduced inner diameter provides high convection rates thanks to the combined pre- and post-dilution configuration. Thus, the use of THERANOVA gives to the haemodialysis capabilities of haemodiafiltration. However, the THERANOVA dialyser should not be used for haemodiafiltration in a reason of a potential enlarging of albumin removal. Expanded haemodialysis is advisable to be used in patients with complications associated with the effects of uremic toxins. Expanded haemodialysis may be a rational therapy for patients who are moving from peritoneal dialysis to HD while waiting for transplantation, which is an example of an individualized, personified approach.

Downloads

Download data is not yet available.

References

Ivanov DD. Research-to-practice “Clinical case in nephrology. 11th REENA™ CME Course”: a review of key issues. Počki. 2018;7(4):291-294. doi: 10.22141/2307-1257.7.4.2018.148518. (in Ukrainian).

Ivanov DD, Pirig LA. Commentary on the KDIGO Guideline on the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD, 2018. Počki. 2018;7(3):208-210. doi: 10.22141/2307-1257.7.3.2018.140205. (in Ukrainian).

Yu X. The evolving patterns of uremia: unmet clinical needs in dialysis. Contrib Nephrol. 2017;191:1-7. doi: 10.1159/000479251.

Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol. 2013 Feb;45(1):139-50. doi: 10.1007/s11255-012-0258-1.

Jankowska M, Cobo G, Lindholm B, Stenvinkel P. Inflammation and protein-energy wasting in the uremic milieu. Contrib Nephrol. 2017;191:58-71. doi: 10.1159/000479256.

Desjardins L, Liabeuf S, Lenglet A, et al. Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins (Basel). 2013 Nov 8;5(11):2058-73. doi: 10.3390/toxins5112058.

Maduell F, Navarro V, Cruz MC, et al. Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low- and high-flux hemodialysis. Am J Kidney Dis. 2002 Sep;40(3):582-9.

Zickler D, Schindler R, Willy K, et al. Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients-a randomized controlled clinical trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024.

Mitra S, Kharbanda K. Effects of expanded hemodialysis therapy on clinical outcomes. Contrib Nephrol. 2017;191:188-199. doi: 10.1159/000479267.

Ronco C, Marchionna N, Brendolan A, et al. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii41-iii47. doi: 10.1093/ndt/gfy202.

Hutchison CA, Wolley M. The rationale for expanded hemodialysis therapy (HDx). Contrib Nephrol. 2017;191:142-152. doi: 10.1159/000479262.

Heyne N. Expanded hemodialysis therapy: prescription and delivery. Contrib Nephrol. 2017;191:153-157. doi: 10.1159/000479263.

Willy K, Girndt M, Voelkl J, et al. Expanded haemodialysis therapy of chronic haemodialysis patients prevents calcification and apoptosis of vascular smooth muscle cells in vitro. Blood Purif. 2018;45(1-3):131-138. doi: 10.1159/000484925.

THERANOVA Limited Controlled Distribution Report 2016. Available from: https://renalcare.baxter.com/sites/g/files/ebysai1471/files/2019-01/EUMP-MG209-16-0038_Theranova_LCD_FINAL.pdf.

Lebourg L, Amato S, Toledano D, Petitclerc T, Créput C. Online hemodiafiltration: is it really more expensive? Nephrol Ther. 2013 Jul;9(4):209-14. doi: 10.1016/j.nephro.2013.03.010. (in French).

Mazairac AH, Blankestijn PJ, Grooteman MP, et al. The cost–utility of hemodiafiltration versus hemodialysis in the Convective Transport Study. Nephrol Dial Transplant. 2013 Jul;28(7):1865-73. doi: 10.1093/ndt/gft045.

Chapdelaine I, de Roij van Zuijdewijn CL, Mostovaya IM, et al. Optimization of the convection volume in online post-dilution hemodiafiltration: practical and technical issues. Clin Kidney J. 2015 Apr;8(2):191-8. doi: 10.1093/ckj/sfv003.

Published

2021-09-08

How to Cite

Ivanov, D. (2021). New era of dialysis: expanded haemodialysis (HDx). KIDNEYS, 8(1), 62–67. https://doi.org/10.22141/2307-1257.8.1.2019.157797

Issue

Section

To Help the Practitioner